QUOIN PHARMACEUTICALS, LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.6375 USD | +1.19% |
|
-10.20% | -87.00% |
| Mar. 15 | Maxim Group Adjusts Quoin Pharmaceuticals Price Target to $4 From $15, Maintains Buy Rating | MT |
| Mar. 14 | Quoin Pharmaceuticals Seeks M&A Opportunities | CI |
Presentation Operator MessageOperator (Operator)Good morning, and welcome to the Quoin Pharmac...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Quoin Pharmaceuticals Ltd, former Cellect Biotechnology Ltd, is an Israel-based specialty pharmaceutical company, focused on developing and commercializing therapeutic products that treat rare and orphan diseases. The Companyâs first lead product is QRX003, a once daily, topical lotion comprised of a broad-spectrum serine protease inhibitor, formulated with the proprietary Invisicare technology, to treat Netherton Syndrome. The product going to be developed for other rare dermatological diseases including Peeling Skin Syndrome, SAM Syndrome, and Palmoplantar Keratoderma. Quoin is also developing QRX004 as a potential treatment for Dystrophic Epidermolysis Bullosa, and QRX006 as a potential therapy for an, as of yet, undisclosed rare skin disease.
Calendar
2024-05-05
- Q1 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
0.6375
USD
Average target price
5.8
USD
Spread / Average Target
+809.80%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -87.00% | 2.35M | |
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- QNRX Stock
- News Quoin Pharmaceuticals, Ltd.
- Transcript : Quoin Pharmaceuticals, Ltd., Q1 2023 Earnings Call, May 09, 2023
